P. Dô

发表

Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients

N. Aide, C. Lasnon, R. Gervais, 2013, European Journal of Nuclear Medicine and Molecular Imaging.

18F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer

Dimitris Visvikis, Mathieu Hatt, Nicolas Aide, 2016, European Journal of Nuclear Medicine and Molecular Imaging.

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.

S. Lantuejoul, D. Planchard, O. Molinier, 2019, The Lancet. Oncology.

Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial

L. Thiberville, D. Planchard, O. Molinier, 2017 .

Utility of serum anti‐cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab

B. Chauffert, E. Babin, S. Dakpé, 2017, British journal of clinical pharmacology.

Oxaliplatin-induced bronchiolitis obliterans organizing pneumonia following hyperthermic intraperitoneal chemotherapy.

R. Gervais, P. Dô, C. Dubos-Arvis, 2018, Journal of gastrointestinal oncology.

Association between lung cancer somatic mutations and occupational exposure in never-smokers

P. Dumont, D. Moro-Sibilot, C. Paris, 2017, European Respiratory Journal.

Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer

I. Licaj, A. Guizard, N. Aide, 2018, European Journal of Nuclear Medicine and Molecular Imaging.

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)

O. Molinier, P. Dumont, W. Hilgers, 2018, ESMO Open.

Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting.

B. Clarisse, P. Fournel, R. Gervais, 2015, Lung cancer.

Cost‐Effectiveness Analysis of Afatinib versus Gefitinib for First‐Line Treatment of Advanced EGFR‐Mutated Advanced Non–Small Cell Lung Cancers

G. de Pouvourville, D. Moro-Sibilot, C. Chouaid, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Economic Analysis of First‐Line Treatment with Erlotinib in an EGFR‐Mutated Population with Advanced NSCLC

E. Felip, F. de Marinis, R. Rosell, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019

G. Jeannin, F. Guisier, G. Quéré, 2020, Cancers.

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study

D. Planchard, F. Guisier, M. Wislez, 2022, Cancers.

IFCT-GFPC-1101 trial: A multicenter phase III assessing a maintenance strategy determined by response to induction chemotherapy compared to continuation maintenance with pemetrexed in patients (pts) with advanced non-squamous (NSQ) NSCLC.

N. Girard, O. Molinier, J. Mazières, 2017 .

Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14

C. Chouaid, P. Dô, P. Thomas, 2019, Advances in Therapy.

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.

Jie Yang, S. Ou, A. Dingemans, 2017, European journal of cancer.

BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers

H. Blanché, J. Trédaniel, G. Zalcman, 2015, European Respiratory Journal.